Verdict: Justified

Key finding: On 10/21 Abbott reported its best organic growth of the year: comparable sales +7.0% (+5.2% for the first nine months), with adjusted EPS of $1.42, +9.2%. The same day it announced a tax-free spin-off of its $8.5B Nutrition business by the end of 2027. That's the segment carrying the infant-formula (NEC) litigation. The full-year sales guide was cut to ~6% from 6.5–7.5%, and the stock still went up. Since the 10/21 close it's +5.7% while SPY is −2.2%. On 10/30 it closed at its highest level since 9/4, above all four moving averages.

Scorecard

Ticker Rev last Q ($M) Rev YoY last Q Rev YoY prior Q Gross margin (last Q, trend) Op margin EPS last Q vs yr ago P/S Mkt cap 1-mo price %
ABT 13,013 +14.5% (comparable +7.0%) +13.0% 57.1% (up from 55.8%) 11.3% $0.53 vs $0.94 3.9x $186.6B +7.5%
MDT 9,756 +13.7% +9.9% 65.0% (up) 18.1% $1.14 vs $0.81 3.3x $122.8B +11.9%
SYK 6,520 +7.6% +9.4% 65.2% (flat) 15.9% $1.96 vs $2.22 4.0x $104.8B +6.0%
DXCM 1,344 +11.2% +13.1% 64.3% (up) 24.3% $0.72 vs $0.70 6.3x $32.0B −4.6%
BSX 5,138 +1.4% +7.5% 66.7% (down from 69.9%) 19.1% $0.40 vs $0.50 2.8x $59.8B −3.8%

GAAP figures. ABT's reported growth includes Exact Sciences (closed 3/23/26). MDT's quarter ends 7/31. P/S and market cap are at the 10/30 close.

ABT is middle of the pack: its organic growth (+7.0% comparable) is in line with SYK and below DXCM and MDT, at a middle multiple (3.9x sales). It has the group's lowest GAAP operating margin (11.3%) because of $841M of acquisition amortization and about $1.07B of legal settlements in the quarter. On adjusted numbers EPS grew 9.2%. ABT is also the only name in the group whose growth is speeding up: comparable growth went from +5.2% over nine months to +7.0% in Q3.

Move

Catalyst

Q3 2026 (10/21, before the open), from the 8-K:
- Sales were $13,013M: +14.5% reported, +7.0% comparable (comparable counts Exact Sciences in both years and excludes FX). Adjusted EPS was $1.42 (+9.2%), in line. GAAP EPS was $0.53 (−43.6%).
- Medical Devices +7.8% comparable. Electrophysiology was +15.5% and Rhythm Management +10.0%. Abbott said Volt (its pulsed field ablation system) gained momentum after full U.S. release in August. Inference: Boston Scientific, the PFA leader, grew revenue only 1.4% in its Q3, which fits ABT taking share in electrophysiology, but neither company's numbers prove it.
- Diabetes Care +6.7% comparable, with CGM (Libre) sensors +7.7%. That's slower than Dexcom's +11.2% revenue growth in its Q3. Libre Duo (glucose plus ketone) was FDA-approved in August, and the U.S. launch is planned for December.
- Diagnostics +6.4% comparable. Cancer Diagnostics (Exact Sciences, including Cologuard) was +13.8%. The blood-based SimpleScreen CRC test launched in September. Rapid/Molecular was +0.9%.
- Nutrition +4.9% (Pediatric +8.7%) after shrinking earlier in the year (−2.1% over nine months).
- Guidance: full-year 2026 comparable sales growth cut to ~6.0% from 6.5–7.5%. The EPS range was tightened to $5.50–5.55 (from $5.45–5.60, same midpoint). Q4 EPS is guided to $1.62–1.67. Inference: ~6% for the year, after 5.2% in the first nine months, implies Q4 comparable growth around 8%, faster than Q3.
- Legal cleanup booked in the quarter: about $670M to resolve the Gill case and NEC claims for about 2,000 more infants, plus about $400M to settle DOJ investigations and a qui tam suit.

The Nutrition spin-off (announced 10/21):
- Abbott will distribute a new public Nutrition company to shareholders, tax-free, by the end of 2027. It covers about $8.5B of sales (Similac, Ensure, PediaSure, Pedialyte, Glucerna), with Daniel Salvadori as CEO.
- What remains is about $42B of devices, diagnostics and established pharma.
- The combined dividend is expected to equal Abbott's current one. Abbott says 2026 guidance and the 2027 guidance coming in January are unaffected.
- Not disclosed: which company keeps the NEC litigation, and the one-time separation costs.

Sector

Money is rotating into healthcare. XLV is +9.8% over the past month and +3.3% since 10/21, while SPY is −0.9% and −2.2%. In medtech, ABT (+5.7% since 10/21) and JNJ (+6.0%) lead. Three peers dropped after their own Q3 reports: SYK (−6.4% on 10/30), BSX (−5.8% on 10/28) and JNJ (−5.7% on 10/13). Dexcom beat on 10/29 and rose +3.0% on 10/30, the same day ABT rose +1.6%. Inference: Dexcom's beat likely helped Abbott's CGM business by association.

Risks

Judgement

Justified. The strength since the report has real support behind it:
- organic growth sped up (+7.0% vs +5.2% over nine months), with electrophysiology at +15.5%
- the legal overhang is being cleared with settlements, and the spin-off moves the segment carrying the infant-formula litigation out of the company
- money is rotating into healthcare

The sales-guide cut was the bad news, and the market looked past it: the stock reversed from 97.67 on report day and has closed above all four moving averages, at a 7-week high. What's still unproven is CGM growth against Dexcom and the January 2027 guide.

Sources